WuXi AppTec

About

As a global leader with operations spanning Asia, Europe, and North America, WuXi AppTec offers an extensive range of R&D and manufacturing services that empower the pharmaceutical and life sciences sectors to push the boundaries of discovery and deliver transformative treatments to patients worldwide.

Our unique business models provide integrated, end-to-end services, including chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing, and clinical research services. We also specialize in advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), enhancing our clients' ability to develop healthcare products through cost-effective and efficient solutions.

In 2023, WuXi AppTec was awarded an AA ESG rating from MSCI for the third consecutive year, reflecting our commitment to sustainable practices. Our open-access platform supports over 6,000 customers across more than 30 countries, helping them improve global health outcomes. We are dedicated to realizing the vision that "every drug can be made and every disease can be treated."